These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 26101227)

  • 1. Correction of iron deficiency anaemia using IV CosmoFer in CKD patients with asthma: a prospective study.
    Syed A; Bhandari S
    QJM; 2016 Mar; 109(3):187-90. PubMed ID: 26101227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving efficiency and value in health care. Intravenous iron management for anaemia associated with chronic kidney disease: linking treatment to an outpatient clinic, optimizing service provision and patient choice.
    Bhandari S; Naudeer S
    J Eval Clin Pract; 2008 Dec; 14(6):996-1001. PubMed ID: 18785894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protocol and baseline data for a prospective open-label explorative randomized single-center comparative study to determine the effects of various intravenous iron preparations on markers of oxidative stress and kidney injury in chronic kidney disease (IRON-CKD).
    Ziedan A; Bhandari S
    Trials; 2019 Apr; 20(1):194. PubMed ID: 30947751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of intravenous iron sucrose versus low-molecular-weight iron dextran in chronic kidney disease.
    Sinha S; Chiu DY; Peebles G; Kolakkat S; Lamerton E; Fenwick S; Kalra PA
    J Ren Care; 2009 Jun; 35(2):67-73. PubMed ID: 19432851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The FIND-CKD study--a randomized controlled trial of intravenous iron versus oral iron in non-dialysis chronic kidney disease patients: background and rationale.
    Macdougall IC; Bock A; Carrera F; Eckardt KU; Gaillard C; Van Wyck D; Roubert B; Cushway T; Roger SD;
    Nephrol Dial Transplant; 2014 Apr; 29(4):843-50. PubMed ID: 24170814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of iron deficiency by a bolus intravenous iron dextran in peritoneal dialysis].
    Ficheux M; Cuny P; Lecouf A; Ryckelynck JP; Hurault de Ligny B; Lobbedez T
    Nephrol Ther; 2011 Dec; 7(7):558-61. PubMed ID: 21715234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous iron dextran treatment in predialysis patients with chronic renal failure.
    Dahdah K; Patrie JT; Bolton WK
    Am J Kidney Dis; 2000 Oct; 36(4):775-82. PubMed ID: 11007680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of total dose iron dextran infusion in geriatric patients with chronic kidney disease and iron deficiency anemia.
    Dossabhoy NR; Turley S; Gascoyne R; Tapolyai M; Sulaiman K
    Ren Fail; 2014 Aug; 36(7):1033-7. PubMed ID: 24845687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accelerated total dose infusion of low molecular weight iron dextran is safe and efficacious in chronic kidney disease patients.
    Sinha S; Chiu D; Peebles G; Swoboda P; Kolakkat S; Lamerton E; Fenwick S; Bhandari S; Kalra PA
    QJM; 2011 Mar; 104(3):221-30. PubMed ID: 20956457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamics and safety of ferric carboxymaltose: a multiple-dose study in patients with iron-deficiency anaemia secondary to a gastrointestinal disorder.
    Geisser P; Rumyantsev V
    Arzneimittelforschung; 2010; 60(6a):373-85. PubMed ID: 20648929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous iron supplementation for the treatment of anaemia in pre-dialyzed chronic renal failure patients.
    Mircescu G; Gârneata L; Capusa C; Ursea N
    Nephrol Dial Transplant; 2006 Jan; 21(1):120-4. PubMed ID: 16144853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous iron in chronic kidney disease: haemoglobin change shortly after treatment of patients neither on dialysis nor on erythropoietin.
    Tagboto S; Cropper L; Mostafa S; Turner J; Bailey G; Pugh-Clarke K
    J Ren Care; 2008 Sep; 34(3):112-5. PubMed ID: 18786076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Iron status and benefit of the use of parenteral iron therapy in pre-dialysis Chronic Kidney disease patients.
    Arogundade FA; Soyinka FO; Sanusi AA; Ojo OE; Akinsola A
    Niger Postgrad Med J; 2013 Dec; 20(4):299-304. PubMed ID: 24633272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of rapid (1,000 mg in 1 hr) intravenous iron dextran for treatment of maternal iron deficient anemia of pregnancy.
    Wong L; Smith S; Gilstrop M; Derman R; Auerbach S; London N; Lenowitz S; Bahrain H; McClintock J; Auerbach M
    Am J Hematol; 2016 Jun; 91(6):590-3. PubMed ID: 26971581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia.
    Kalra PA; Bhandari S; Saxena S; Agarwal D; Wirtz G; Kletzmayr J; Thomsen LL; Coyne DW
    Nephrol Dial Transplant; 2016 Apr; 31(4):646-55. PubMed ID: 26250435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of intravenous iron dextran and oral iron in inflammatory bowel disease: a case-matched study in clinical practice.
    Khalil A; Goodhand JR; Wahed M; Yeung J; Ali FR; Rampton DS
    Eur J Gastroenterol Hepatol; 2011 Nov; 23(11):1029-35. PubMed ID: 21857526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American clinical trial.
    Van Wyck DB; Cavallo G; Spinowitz BS; Adhikarla R; Gagnon S; Charytan C; Levin N
    Am J Kidney Dis; 2000 Jul; 36(1):88-97. PubMed ID: 10873877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of Intravenous Iron - Cosmofer and Monofer Therapy in Peritoneal Dialysis and Non-Dialysis-Dependent Chronic Kidney Disease Patients.
    Sivakumar C; Jubb VM; Lamplugh A; Bhandari S
    Perit Dial Int; 2019; 39(2):192-195. PubMed ID: 30858290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic appraisal of maintenance parenteral iron administration in treatment of anaemia in chronic haemodialysis patients.
    Sepandj F; Jindal K; West M; Hirsch D
    Nephrol Dial Transplant; 1996 Feb; 11(2):319-22. PubMed ID: 8671786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxidative stress markers in predicting response to treatment with ferric carboxymaltose in nondialysis chronic kidney disease patients.
    Prats M; Font R; García C; Muñoz-Cortés M; Cabré C; Jariod M; Romeu M; Giralt M; Martinez-Vea A
    Clin Nephrol; 2014 Jun; 81(6):419-26. PubMed ID: 24691014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.